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ABSTRACT
Clostridium difficile infection (CDI) is
increasingly recognized as an emerging
healthcare problem of elevated importance.
Prevention and treatment strategies are
constantly evolving along with the apperance
of new scientific evidence and novel treatment
methods, which is well-reflected in the
differences among consecutive international
guidelines. In this article, we summarize and
compare current guidelines of five international
medical societies on CDI management, and
discuss some of the controversial and currently
unresolved aspects which should be addressed
by future research.
Keywords: Clostridium difficile infection (CDI);
CDI recurrence risk; CDI severity; Contact
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INTRODUCTION
The worldwide increasing burden of Clostridium
difficile infection (CDI) has converted the quest
for optimal treatment strategies into one of the
hottest topics in the field of nosocomial
infectious diseases. The incidence of CDI have
been steadily growing in the past decades [1],
partially due to an increasing awareness of the
disease, but mainly because of an important
increase in the susceptible population during
this period, such as the elderly or the
immunocompromised [2], the appearance of
BI/NAP1/027 [3] and other hypervirulent C.
difficile strains and a growing prevalence of
asymptomatic C. difficile carriage [4]. Patients
with CDI have increased length of hospital stay,
higher readmission rates, more elevated
inpatient costs and higher mortality than
patients without CDI [5–7].
Boards of experts approving clinical
guidelines constantly have to cope with the
lack of sound scientific evidence on important
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aspects of CDI management, such as the precise
definition of CDI severity [8–11], duration of
contact isolation measures [12], or the
indications and optimal time of surgical
intervention [13]. The consequence of this
situation is the coexistence of guidelines with
certain differences in their recommendations
that may raise doubts in the minds of treating
physicians at the time of clinical decision
making [14]. This insecurity, in turn, may also
contribute to the low adherence to existing
guidelines observed in various studies [15–17].
Indeed, an elevated proportion of clinicians
agree on the main points where current CDI
management practices could and should be
improved [18].
In the following, we present a critical
summary and comparison of the latest
international guidelines published by five
international societies on the management of
CDI, and briefly discuss some of the most
controversial and currently unresolved
questions in this field in the light of the most
up-to-date available evidence. This article is
based on previously conducted studies and
does not involve any new studies of human or
animal subjects performed by any of the
authors.
CURRENT GUIDELINES ON CDI
MANAGEMENT
There are a number of guidelines and
recommendations on the prevention and
treatment of CDI approved by national expert
boards in various countries [19–25]. In this
article, however, we will center our attention
on seven international guidelines published in
the last 6 years, reviewing and comparing their
recommendations on three fundamental
aspects of CDI management: contact isolation
measures, pharmacological therapy, and
surgical treatment.
Five of these guidelines offer guidance on the
treatment of CDI: the 2010 guidelines of the
Society for Healthcare Epidemiology of America
(SHEA) and the Infectious Diseases Society of
America (IDSA) 2010 [26]—whose updated
version is under progress at the publication of
this article; the 2013 guidelines of the American
College of Gastroenterology (ACG) [27]; the
2014 guidelines of the European Society of
Clinical Microbiology and Infectious Diseases
(ESCMID) [28]; the 2015 guidelines of the
World Society of Emergency Surgery (WSES)
[29]; and the most recent 2016 update of the
2011 guidelines of the Australasian Society for
Infectious Diseases (ASID) [30, 31]. This last
document also deals with CDI treatment in
children, but we will focus exclusively on the
recommendations made for adult patients.
Three of the above guidelines (IDSA/SHEA,
ACG and WSES) include direct
recommendations on contact isolation
measures, whereas the ESCMID guidance
document makes reference to separate
guidelines approved by the same society on
CDI spread control [32]. The new ASID
guidelines pay only marginal attention to this
issue, but there is a position statement on
infection control measures in CDI published
by the same society (in collaboration with the
Australian Infection Control Association, AICA)
in 2011 [33] which is referred to by the
previous, 2011 treatment guidelines as the one
recommended to follow. The recommendations
of these two guidelines supported by the
ESCMID and the ASID will also be taken into
consideration in the following analysis.
The ASID document on CDI management
[31] does not indicate recommendation
strength and evidence quality, whereas the
ASID/AICA guidelines on CDI prevention [33]
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use the same grading system as the IDSA/SHEA
guidelines. On the other hand, the two
documents backed by the ESCMID [28, 32] use
different grading systems. Supplementary
Table 1 compares the different criteria utilized
by these documents for the strength of each
individual recommendation and the quality of
evidence on which it is based.
CONTACT ISOLATION MEASURES
Human-to-human transmission of C. difficile
was first suspected in the early 1980s [34], and
today there is wide consensus on the
importance of applying contact isolation
measures in diagnosed CDI cases. The
examined guidelines, however, differ in certain
details in their recommendations in this respect
which are worth mentioning.
Whereas hand washing with soap and water is
only recommended in the outbreak setting or in
cases of elevated CDI rate according to the IDSA/
SHEA guidelines, and the ASID/AICA
recommend it only in cases of not having used
gloves and directly soiled hands, the rest of the
societies strongly recommend the use of soap and
water after being in contact with CDI patients.
The duration of contact precautions until at
least 48 h after diarrhea resolution is a point
emphasized by the non-US guidelines, whereas
the IDSA/SHEA and ACG guidelines do not
make clear recommendations on the exact time
of discontinuation of contact precautions They
refer instead to ‘‘the resolution of diarrhea’’ as a
necessary condition for this, without further
specifications, although the 48-hour-rule is
mentioned as a possible strategy by the ACG
guidelines.
There is consensus among the five guidelines
in the preference of chlorine-containing
disinfection agents for the cleaning of patient
rooms and the equipment used in CDI cases.
The minimum allowed chlorine concentration
of these solutions, however, is higher in the
ACG guidelines than the other documents
(5000 vs. 1000 ppm). The ASID/AICA and the
ESCMID guidelines also emphasize the
importance of thorough terminal room
cleaning after discharge or transfer of a CDI
patient, and the ESCMID also recommends
additional immediate cleaning to take place in
cases of environmental fecal contamination.
The details of the individual recommendations
are summarized in Table 1.
Unresolved Issues
According to recent evidence, stool, skin, and
environmental contamination after a resolved
CDI episode persist in a considerable proportion
of cases, and C. difficile shedding by cured
patients may be as high as 50% 1–4 weeks
after the end of treatment [12]. This
phenomenon can lead to a higher hand
contamination rate of healthcare personnel
caring for these patients that, in turn, may
increase the risk of in-ward C. difficile
transmission [35]. In light of these data,
maintaining contact precautions after a treated
CDI episode until discharge may be of potential
benefit in terms of CDI spread control.
Related to this problem is the screening of
asymptomatic C. difficile carriers at hospital
admission, which has recently also been in the
focus of attention. Apart from a series of
mathematical models that demonstrate the
cost-effectiveness of this practice [36–38], a
recent quasi-experimental study reported a
significant decrease in CDI incidence after the
implementation of this measure [39]. If the
screening of potential C. difficile carriers in the
hospital will ever form part of guideline
recommendations depends on the results of
future studies addressing this issue.
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PHARMACOLOGICAL THERAPY
The summary of pharmacological treatment
recommendations of the five CDI guidelines
can be found in Table 2.
Initiation of Pharmacological Treatment
All five expert boards lay special emphasis in
their recommendations on the withdrawal of
unnecessary systemic antibiotic treatment upon
CDI diagnosis (recommendation strengths
IDSA/SHEA: A-II; WSES: 1-C; ACG: strong/
high-quality; ESCMID and ASID: no strength
of recommendation indicated). There are,
however, greater differences among these
documents in the recommendations on the
when and how of the initiation of specific
anticlostridial treatment. The ESCMID
guidelines advocate a 48-h ‘‘wait-and-see’’
policy after stopping all systemic antibiotics
for the initial management of a first non-severe
episode of CDI (recommendation C-II). In
contrast, the IDSA/SHEA guidelines and the
WSES guidelines recommend initiating empiric
antibiotic treatment in all cases of strong
suspicion of CDI even before microbiological
confirmation is available (recommendation
C-III and 1B, respectively), whereas the ACG
guidelines recommend full treatment in this
scenario even in cases of negative
microbiological results (strong
recommendation, moderate-quality evidence).
This last document also suggests the prompt
initiation of empiric therapy in the particular
case of severe colitis in a patient with
inflammatory bowel disease (conditional
recommendation, low-quality evidence). The
ASID guidelines chose a different approach to
this problem, advising laboratories to perform
automatic tests for the presence of toxigenic C.
difficile on every unformed stool sample they
receive from hospitalized patients, even in the
absence of the specific request form.
Unresolved Issues
Empirical treatment of CDI before the
collection of stool specimens may be
inevitable in certain cases, as recommended by
three of the five analyzed guidelines. It has to be
borne in mind, however, that the proportion of
a false negative microbiological test may reach
14% after 1 day, and up to 45% after 3 days, of
treatment, independently from the detection
method used [40]. These same three guidelines
accept the use of PCR on rectal swab specimens
for CDI diagnosis in patients with ileus, but
there are no recommendations about the use of
this method in the case of an anticipated delay
in stool specimen collection for other reasons.
On the other hand, PCR tests without the
direct detection of C. difficile toxins may lead to
overdiagnosis of CDI, as it cannot differentiate
between infection and colonization [41], and an
erroneous diagnosis of CDI may lead to
unnecessary treatment and to the delay in
some cases of further efforts to find the real
cause of the symptoms.
Treatment Choice According to CDI
Severity
The appearance of life-threatening complications,
such as shock, bowel perforation or peritonitis, are
clear signs of a severe CDI, but there is considerably
less consensus on other patient and/or disease
parameters that would predict an unfavorable
disease course and warrant a more aggressive
initial therapy. Although all examined guidelines
differentiate between mild-moderate and severe
CDI, there are great differences among the exact
criteria they use to define these categories.
The ESCMID guidelines recognize the
difficulty of precisely defining CDI severity,
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but offers an extensive list of clinical and
laboratory markers in the presence of which
severe CDI may be established, and mentions
older age, serious comorbidity,
immunodeficiency and ICU admission as
additional criteria for an increased risk of a
severe disease. Similarly, the WSES guidelines
also refer to the absence of consensus on the
definition of severe CDI, and make its
recommendations based on risk factors for an
unfavorable disease course. The ASID document
defines severe CDI as two or more signs or
symptoms from a list similar to the one found
in the ESCMID guidelines, and names toxic
megacolon, ICU admission, need of surgery and
death due to CDI as determinants of a
complicated disease course. In the US-based
guidelines (IDSA/SHEA and ACG),
severe-complicated CDI is specified as an
additional disease severity grade, again with
important differences between the ways it is
defined by the two expert boards. The
individual criteria to define severe CDI or an
elevated risk for severe CDI according to the five
guidelines are summarized in Table 3.
All five guidelines agree on recommending
oral metronidazole as the first choice of
antibiotic in case of mild-moderate CDI in the
absence of risk factors for recurrence and oral
vancomycin in the presence of severe CDI. The
ACG, WSES and ASID documents also
recommend changing metronidazole for
vancomycin when no improvement is
observed after 3–7 days of treatment (ACG:
strong recommendation and moderate-quality
evidence; WSES: 1-A recommendation).
The recommended therapy for
severe-complicated disease according to the
IDSA/SHEA and ACG guidelines should be
based on the combination of vancomycin
administered orally or via nasogastric tube and
intravenous metronidazole, with the addition
of rectal vancomycin in the presence of ileus
(recommendation C-III and strong/low-quality
evidence, respectively). The other three boards
of experts, however, recommend the
combination of enteric vancomycin and
intravenous metronidazole to be reserved for
severe cases when oral intake is impossible or
contraindicated (ESCMID, WSES and ASID), or
as second-line therapy in case of
non-responders to vancomycin monotherapy
(ASID). In cases of oral intolerance, the ESCMID
document also supports the use of intravenous
tigecycline, although only with a
recommendation grade of C-III, a treatment
option also mentioned in the ASID guidelines,
as a 3rd line therapy for severe CDI refractory to
the combination of vancomycin and
metronidazole.
Unresolved Issues
It is remarkable that only one of the guidelines
[28] mention older age as a factor associated
with CDI severity, despite its notoriously being
reported as an important predictor of
unfavorable outcome [8, 42]. Different studies
suggest different age cut-off values to predict a
severe disease course [43–48]. This makes sense,
because a single, well-definable cut-off most
probably does not exist, as it is suggested by
results showing a linear or quasi-linear
relationship between these factors and disease
severity or mortality [49–52]. The threshold of
65 years as proposed by the ESCMID guidelines
may be an acceptable choice [28], but curiously
none of the three studies referred to by the
authors to support this choice use this exact age
cut-off [8, 44, 47]. It seems evident that the
precise impact of age on CDI severity needs
further clarification.
The burden of comorbid conditions is also
known to be associated with a severe course of
CDI [8, 42], and yet it is only mentioned in
Infect Dis Ther (2016) 5:207–230 217
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relation to CDI severity in the ESCMID
guidelines [28]. A great number of individual
comorbid illnesses have been related to
increased CDI severity and mortality in
previous studies, such as malignant diseases
[47, 53, 54], chronic renal failure [47, 55],
cardiopulmonary conditions
[47, 52, 54, 56–58], diabetes mellitus [52, 57],
inflammatory bowel disease [54, 59, 60], or liver
cirrhosis [50, 54, 61]. While it may be difficult to
handpick a complete and exclusive list of
comorbid conditions related to severe
outcome, it seems clear that a greater number
of underlying illnesses and comorbid
conditions of higher severity entail worse CDI
prognosis. The most frequently evaluated
comorbidity index that aims to embrace all
these underlying diseases is the Charlson
Comorbidity Index (CCI) [52, 62–65], followed
by the American Society of Anesthesiologists
(ASA) physical status classification system
[48, 66], and Horn’s index [67]. All of them
have demonstrated good correlation with CDI
severity and poor outcome. The superiority of
any of these comorbidity scales over the rest has
not been investigated in this respect, but there
seems to be sufficient evidence available for
their future inclusion among CDI severity risk
factors.
In contrast to age and comorbidity,
computer tomography (CT) findings and the
presence of pseudomembranes as evidenced by
colonoscopy are both included as markers of
severe disease in more than one current set of
guidelines [28, 31], albeit based on rather
dubious scientific evidence. Although CT scan
is a useful tool to diagnose toxic megacolon
[68], other specific radiological findings do not
seem to correlate indubitably well with CDI
severity [69, 70]. Similarly, endoscopic findings
with or without colon biopsy may help
clarifying diarrhea etiology in cases of a high
clinical suspicion and a negative C. difficile stool
test [71], but the presence of
pseudomembranous colitis seems to be a less
CDI-specific finding than it is generally believed
to be [72], and its relationship with severe
outcome has not been demonstrated either [73].
Oral vancomycin combined with
intravenous metronidazole is the treatment of
choice in severe-complicated CDI according to
the IDSA/SHEA and ACG guidelines. This
combination was recently reported to be
superior to vancomycin monotherapy in terms
of mortality in a retrospective study in critically
ill CDI patients [74], but a posterior animal
model did not confirm these results [75], and a
meta-analysis comparing the efficacy and safety
of vancomycin therapy with combination
regimens did not find any benefit of this
combination either [76]. Moreover, this last
study demonstrated a higher rate of adverse
events (including higher mortality) in patients
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guidelines do not give preference to
combination therapy over vancomycin
monotherapy in severe CDI, but randomized
controlled trials evaluating this question have
not yet been performed.
Recurrent CDI
CDI recurrence is defined by three of the
guidelines as a reappearance of documented
CDI either within 8 weeks of completion of
anticlostridial treatment (ACG) or within the
8 weeks following the onset of the first episode
(ESCMID and ASID), while the remaining two
documents do not define an exact time-frame
for recurrent CDI. Most of these guidelines
mention some risk factors for recurrent CDI in
a tangential manner, but the ESCMID guidance
document offers the most comprehensive list of
these factors: age over 65 years, continued use
of antibiotics after CDI diagnosis, severe
comorbidity including renal failure, more than
one previous CDI episode, use of proton pump
inhibitors, and a severe initial CDI.
The majority of the examined guidelines
recommend using the same antibiotic in a
second CDI episode that had been prescribed
for the first one with reasonable adjustments
according to disease severity. In the ESCMID
guidelines, however, fidaxomicin and
vancomycin both have a B-I recommendation
for recurrent disease, whereas the use of
metronidazole is only marginally supported in
this setting (recommendation C-I). Moreover,
the most recent ASID document directly
discourages from using metronidazole in
recurrent CDI.
Unresolved Issues
General consensus on the precise definition of
the patient population at an elevated recurrence
risk is still lacking, though the evidence available
is somewhat more consistent than in the case of
disease severity. The risk factors listed by the
ESCMID guidelines are largely in accordance
with the conclusions of two meta-analyses and
a systematic review performed on this topic
[42, 77, 78]. More recent studies greatly support
these previous results, but also name additional
risk factors for recurrent CDI not mentioned by
any of the current guidelines. In a retrospective,
but very extensive cohort, steroid treatment was
found to be associated with recurrent CDI [79],
and a very recent prospective cohort identified
enteral tube nutrition as another independent
predictor of recurrence [80]. In another report on
a retrospective cohort of more than 750 patients,
the authors found a longer hospital stay to
independently predict recurrent CDI [81], and
there is growing evidence that inflammatory
bowel disease may also predispose to CDI
recurrence [82]. It is also important to mention
that proton pump inhibitor treatment, although
it has been associated with CDI relapse on
multiple occasions [78, 81, 83], still remains
one of the most controversial recurrence risk
factors, with at least two recent studies published
with negative results on this supposed
relationship [84, 85].
In intestinal graft-versus-host disease
(GVHD), a potentially elevated recurrence risk
is not clearly established. In this conditions,
however, the clinical manifestation of a flare of
the underlying disease may be confounded with
CDI, and CDI may also worsen the prognosis of
GVHD [86, 87]. For this reason, taking special
care to optimize initial CDI treatment in this
patient population in order to minimize
recurrences may be beneficial. However, this
underlying condition is not mentioned by any
of the current international guidelines.
Given that the reason behind
four-times-a-day administration of
vancomycin is to be sought in the fast
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elimination of the drug from the colon of a
patient with severe diarrhea, maintaining this
same dosing frequency after diarrhea resolution
may not be absolutely necessary. In fact,
decreasing vancomycin dosing frequency at
this point could potentially help prevent
additional unnecessary damage to the
intestinal microbiota without increasing
treatment failure rate or recurrence risk. In a
recent in vitro study on alternative dosing
regimens of fidaxomicin, a shortened
fidaxomicin course followed by a pulsed or
tapered regimen enhanced the recovery of
intestinal bifidobacteria population without
losing efficacy in terms of the resolution of
simulated CDI [88]. Similar studies with
vancomycin, however, have not yet been
performed.
Based on a similar argument, in patients that
promptly respond to antibiotic treatment with
normalization of their bowel habit, completing
the recommended overall treatment duration of
10–14 days may not be completely
indispensible. Though one can suspect that
shorter antibiotic courses could lead to higher
recurrence rates, no overwhelming evidence
exists about this relationship [89]. Until
further research answers these intriguing
questions, however, adherence to the now
generally accepted dosage regimens of
currently used anticlostridial drugs is
recommended.
Multiple Recurrent CDI
Fidaxomicin, the newest incorporation in the
antibiotic armament against C. difficile with a
significantly greater capacity to reduce
recurrence risk as compared to metronidazole
or vancomycin, was first approved in 2011 in
the US,and it was also introduced gradually in
the European market during the three following
years (first in the UK, the Nordic countries and
Austria, and later in the Czech Republic, France,
Hungary, Portugal, Slovakia and Spain in 2012,
followed by the rest of Europe during the years
2013 and 2014). From 2012 on, fidaxomicin has
also gained authorization progressively in the
rest of the globe, such as in Japan, Canada,
Australia, South Africa or the Middle East
countries. As a consequence, the 2010 IDSA/
SHEA guidelines do not make reference to this
antibiotic, and in the 2013 ACG guidelines, it is
mentioned, albeit not recommended for
insufficient available evidence on its
superiority as compared to vancomycin by
that time, and for its rather elevated cost.
The recent apparition of fidaxomicin is the
main reason why the most relevant differences
in the examined guidelines can be found in
their recommendations for the management of
multiple CDI recurrences. The IDSA/SHEA
guidelines—published in the pre-fidaxomicin
era—recommend vancomycin treatment with
taper or pulse regimens from the second
recurrence on, as do the 2013 ACG guidelines
(the first one that appeared after the approval of
fidaxomicin in the US). In the 2014 ESCMID
document, the use of vancomycin taper or pulse
regimen and fidaxomicin obtained the same
level of recommendation for multiple
recurrences (B-II). This is also the first
guidance document that overtly discourages
clinicians from using metronidazole in this
situation due to a higher risk of recurrences
(D-II). It is to be remarked that metronidazole
was already considered a bad antibiotic choice
for multiple recurrences by the IDSA/SHEA ASID
and ACG guidelines, but mainly because of its
potential for cumulative neurotoxicity and not
for its suboptimal efficacy. According to the
WSES guidelines, the use of vancomycin and
fidaxomicin in multiple recurrent CDI are also
equally recommended (1-B). This document, as
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well as the ESCMID guidelines, also advocates
the use of fidaxomicin in first episodes of CDI in
patients with an elevated risk of recurrence
(recommendations 1-A and B-I, respectively).
On the other hand, the most recent ASID
guidelines do not recommend fidaxomicin in
first episodes due to uncertainty about
cost-effectiveness as compared to conventional
treatment options, and suggests its use from the
second recurrence on or as second-line
treatment in refractory CDI.
The use of intestinal microbiota
transplantation has also gained a more central
role in multiple recurrent and refractory CDI
over the past years. It is only briefly mentioned
as an alternative treatment option in the oldest
guidelines (IDSA/SHEA), whereas it is already
included among the recommendations of the
ACG guidelines, though only as a conditional
recommendation supported by
moderate-quality evidence. In more recent
guidelines, however, its grade of
recommendation for multiple CDI recurrences
is equal (WSES: 1-B) or even higher (ESCMID:
A-I) than that of vancomycin or fidaxomicin
(1-B and B-II in the WSES and ESCMID
guidelines, respectively). Intestinal microbiota
transplantation is also considered by the ASID
as equally valid as a treatment option for
multiple recurrences as fidaxomicin or
vancomycin, and further as a good second-line
therapy choice after vancomycin failure in
refractory CDI. This most recent guidelines
also state their recommendations about the
optimal transplant protocol.
Unresolved Issues
The role of fidaxomicin in multiple recurrent
CDI is unquestionable today. There is growing
evidence, however, demonstrating that it may
be more cost-effective than vancomycin or
metronidazole in recurrent CDI and also as a
first-line treatment [90–93]. In a study
presenting real-world data on fidaxomicin use
in seven English hospitals, the most significant
reduction in CDI recurrence rates after the
introduction of fidaxomicin was observed in
the centers where it was used as first-line
treatment in all CDI cases [94]. Fidaxomicin
use, moreover, seems to lead to less
environmental C. difficile contamination,
which may have a positive impact on
in-hospital C. difficile spread [95], and since it
does not significantly alters gut microbiota, its
use may also reduce the risk of intestinal
colonization by multiresistant bacteria in
comparison with vancomycin treatment [96].
If these data are confirmed by forthcoming
studies, fidaxomicin will probably gain a more
central role in CDI treatment.
The administration of vancomycin via
nasogastric tube is a generally accepted
practice, but fidaxomicin is only
recommended by current guidelines to be
administered orally. According to recent data,
this may be a safe and efficient treatment
option when oral intake is impossible [97–99].
Future guidelines may consider this fidaxomicin
administration method for CDI patients with an
elevated recurrence risk and impaired oral
intake.
Intestinal microbiota transplantation
represents an approach that is markedly
different from other current CDI therapies that
may even have a deleterious collateral effect on
the intestinal microbiota [100]. Despite the
need of a rather complex infrastructure to
perform this intervention [101–103], its
advantages clearly outweigh the
inconveniences. Due to the reconstitution of a
healthy intestinal microbiota, this treatment
method has demonstrated an excellent clinical
efficacy in recurrent CDI [104], and has also
been proved to be cost-effective as compared to
222 Infect Dis Ther (2016) 5:207–230
vancomycin and even fidaxomicin
[91, 105, 106]. It is becoming available in an
increasing number of centers worldwide, and
the recently demonstrated efficacy of frozen
and encapsulated microbiota administered
orally makes it an ever more attractive
treatment choice [107]. Based on these
promising results, it may only be a matter of
time until oral microbiota therapy becomes the
backbone of the treatment of recurrent and
refractory CDI.
Probiotics and Immunotherapy
The role of probiotics and immunotherapy in
CDI is controversial, and this is clearly reflected
in the discordant recommendations on their
use among the examined guidelines.
The WSES guidelines are the only ones which
do not recommend directly against the use of
probiotics in CDI treatment. It suggests that
probiotics may be of use as adjunctive therapy
for recurrent CDI (2-B), whereas the other four
guidelines consider their utilization not to be
recommended in any scenario (IDSA/SHEA:
C-III; ACG: moderate recommendation,
moderate-quality evidence; SCMID: D-I).
Immunotherapy is only marginally
mentioned by the IDSA/SHEA and the ASID
guidelines without formulating concrete
recommendations with respect to them, and
the other guidelines make only very weak and
cautious recommendations on this issue. The
ACG guidelines consider the addition of
intravenous immunoglobulin to the antibiotic
treatment potentially helpful in patients with
hypogammaglobulinemia (strong
recommendation, low-quality evidence),
whereas the WSES document recommends its
use only in the case of multiple recurrences or
fulminant CDI (2-C). The WSES guidelines
suggest that monoclonal antibodies to toxins
A and B may also be of some benefit in
preventing CDI recurrences, especially in CDI
caused by the hypervirulent strain 027 (2-C).
The ESCMID guidance document assigns a C-I
recommendation to the use of monoclonal
antibodies combined with vancomycin or
metronidazole in first episodes of CDI.
Curiously, this last document supports the
potential use of passive immunotherapy with
immune whey after completing oral antibiotic
therapy in an initial CDI episode in order to
reduce the recurrence risk (C-II), while its use in
multiple recurrences is advised against (D-I).
Unresolved Issues
Probiotics are currently not recommended for
the treatment of CDI or for the prevention of
CDI recurrence by the majority of the analyzed
guidelines. A recent meta-analysis, however,
demonstrated its efficacy in primary CDI
prophylaxis in patients receiving systemic
antibiotic treatment [108]. Hence, they may be
considered for this indication by future
guidelines.
The recommendations regarding
immunotherapy may also change substantially
in the future, given that the monoclonal
antibody bezlotoxumab efficiently prevented
CDI recurrence in two recent randomized
controlled trials [109]. Moreover, there are also
various vaccines against C. difficile under
development, the most advanced of which
[110] is currently being evaluated in a phase
III clinical trial (NCT01887912).
SURGICAL TREATMENT
Different guidelines refer to the ‘‘severely ill
patient’’ (IDSA/SHEA), patients with ‘‘systemic
inflammation and deteriorating clinical
condition despite maximal antibiotic therapy
(with) toxic megacolon, acute abdomen, and
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severe ileus’’ (ESCMID), or ‘‘patients with
fulminant colitis’’ (WSES) as candidates for
surgical treatment. Indications for surgery
according to the ASID guidelines are toxic
megacolon, bowel perforation or severe
deterioration in spite of first and second line
medical therapy. The ACG guidelines seem to
offer the most detailed recommendations for
surgical consultation, suggesting it to be
solicited in all severe-complicated CDI cases
with one or more of the following
characteristics: hemodynamic instability
requiring vasopressors, clinical sepsis with
organ failure, changes in mental status,
extreme leukocytosis (C50,000 cells/lL),
elevated lactic acid serum levels (C5 mmol/L),
or evidence of treatment failure after 5 days of
conservative therapy (strong recommendation,
moderate-quality evidence). Most guidelines,
however, also call attention to the potentially
disastrous consequences of a delayed
intervention in cases where it is indicated,
recommending performing surgery before
patient serum lactate levels reach 5 mmol/L in
order to keep perioperative mortality to a
minimum.
Subtotal colectomy with the preservation of
the rectum and end-ileostomy is the
intervention of choice for the surgical
treatment of CDI. Based on a case-controlled
series published in 2011, however, diverting
loop ileostomy and colonic lavage followed by
intravenous metronidazole and vancomycin
administered via the efferent limb of the
ileostomy seems to be a good alternative to
total colectomy in selected patients [111]. This
novel colon-sparing method is mentioned by
the ACG, ESCMID and ASID guidelines, and
obtains a 2-C recommendation level in the
WSES document.
Unresolved Issues
An emergency surgical intervention is indicated
without any doubt in cases of colonic
perforation and peritonitis. However, the exact
patient population that could benefit from
non-emergency surgery, and the optimal
time-point of such an intervention are issues
less clearly defined. According to two
meta-analyses, prompt surgical intervention
can reduce mortality in severe CDI [13, 112].
However, the authors of both of these studies
admit that the optimal time-point for surgery is
difficult to identify. The WSES guidelines also
clearly state that there are no clinical or
laboratory data currently that could reliably
predict the eventual need of surgery in CDI
patients. Future research should focus on a
clearer definition of the precise indications
and the optimal time of surgery in these
patients.
A randomized controlled trial comparing
diverting loop ileostomy with colectomy in
severe CDI cases was prematurely terminated
because of a low number of eligible patients
(NCT01441271), but there is another clinical
trial on the same issue that is currently
recruiting participants (NCT02347280). This
study may provide additional quality evidence
to recommend the use of this promising new
technique in everyday practice [113].
CONCLUSION
Clostridium difficile infection is one of the
greatest burdens of modern medicine and
probably will remain so in the foreseeable
future. This is reflected in the increasing
interest in CDI management of clinicians and
researchers alike. Frequently updated
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international guidelines are essential to provide
the best available evidence-based therapy for
most CDI patients. Current CDI guidelines are
useful tools in achieving this goal, yet there are
still a number of open questions about optimal
CDI management that upcoming research has
to address so that new guidelines updates can
improve their recommendations for the benefit
of these patients.
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